載入中
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
一般交易時段
US$0.94
−US$0.0299 · -3.08%
盤中時間採用ET。市場資料可能有所延遲。
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
日內區間
目前US$0.94
52週區間
目前US$0.94
盤中時間採用ET。市場資料可能有所延遲。
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
日內區間
目前US$0.94
52週區間
目前US$0.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 101.6萬 USD | 133.6萬 USD | 32.6萬 USD | 28.7萬 USD | 23.4萬 USD |
| 銷貨成本 | 56.3萬 USD | 68.2萬 USD | 4000 USD | 9000 USD | 105.3萬 USD |
| 毛利 | 45.3萬 USD | 65.4萬 USD | 32.2萬 USD | 27.8萬 USD | −81.9萬 USD |
| 研究與開發 | 1530.6萬 USD | 1285.1萬 USD | 1244.6萬 USD | 1574.5萬 USD | 2437.7萬 USD |
| 銷售、一般及管理費用 | 1029.9萬 USD | 997.9萬 USD | 1003.4萬 USD | 1177.9萬 USD | 1745萬 USD |
| 營業費用 | 2539.1萬 USD | 2283萬 USD | 2248萬 USD | 2752.4萬 USD | 4077.4萬 USD |
| 利息收入 | 48.8萬 USD | 114.4萬 USD | 131.4萬 USD | 108.4萬 USD | 58.1萬 USD |
| 利息支出 | −93.2萬 USD | 87.3萬 USD | 86.6萬 USD | 84.3萬 USD | 88.7萬 USD |
| 折舊和攤銷 | 51.1萬 USD | 31.6萬 USD | 25.3萬 USD | 36.2萬 USD | 105.3萬 USD |
| 營業利益 | −2493.8萬 USD | −2217.6萬 USD | −2215.8萬 USD | −2724.6萬 USD | −4159.3萬 USD |
| 淨利 | −2382.1萬 USD | −2258.3萬 USD | −2088.8萬 USD | −2832.1萬 USD | −4124.2萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
